Joseph FG, Hirst CL, Pickersgill TP, Ben-Shlomo Y, Robertson NP, Scolding NJ. CSF oligoclonal band status informs prognosis in multiple sclerosis: A case control study of 100 patients. Journal of Neurology, Neurosurgery, and Psychiatry. 2009; 80(3):292–6. [DOI:10.1136/jnnp.2008.150896] [PMID]
Hanken K, Eling P, Hildebrandt H. The representation of inflammatory signals in the brain - a model for subjective fatigue in multiple sclerosis. Frontiers in Neurology. 2014; 5:264. [DOI:10.3389/fneur.2014.00264] [PMID] [PMCID]
Laule C, Leung E, Li DK, Traboulsee AL, Paty DW, MacKay AL, et al. Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Multiple Sclerosis Journal. 2006; 12(6):747–53. [DOI:10.1177/1352458506070928] [PMID]
Ponichtera-Mulcare J. Exercise and multiple sclerosis. Medicine & Science in Sports & Exercise. 1993; 25(4):451–65. [PMID]
Goldenberg MM. Multiple sclerosis review. Physical Therapy. 2012; 37(3):175–84. [PMID] [PMCID]
Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KHG. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clinical & Experimental Immunology. 2010; 162(1):1–11. [DOI:10.1111/j.1365-2249.2010.04143.x] [PMID] [PMCID]
Trapp BD, Nave KA. Multiple sclerosis: An immune or neurodegenerative disorder? Annual Review of Neuroscience. 2008; 31:247–69. [DOI:10.1146/annurev.neuro.30.051606.094313] [PMID]
McFarland HF, Martin R. Multiple sclerosis: A complicated picture of autoimmunity. Nature Immunology. 2007; 8(9):913–9. [DOI:10.1038/ni1507] [PMID]
Barnett MH, Prineas JW. Relapsing and remitting Multiple Sclerosis: Pathology of the newly forming lesion. Annals of Neurology. 2004; 55(4):458–68. [DOI:10.1002/ana.20016] [PMID]
Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. The Lancet Neurology. 2006; 5(4):343–54. [DOI:10.1016/S1474-4422(06)70410-0]
Thompson A. Primary progressive multiple sclerosis. Brain. 1997; 120(6):1085–96. [DOI:10.1093/brain/120.6.1085] [PMID]
Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: Insights from pathology. Current Opinion in Neurology. 2014; 27(3):271–8. [DOI:10.1097/WCO.0000000000000094] [PMID] [PMCID]
Río J, Comabella M, Montalban X. Multiple sclerosis: current treatment algorithms. Current Opinion in Neurology. 2011; 24(3):230–7. [DOI:10.1097/WCO.0b013e328346bf66] [PMID]
Loma I, Heyman R. Multiple sclerosis: Pathogenesis and treatment. Current Neuropharmacology. 2011; 9(3):409–16. [DOI:10.2174/157015911796557911] [PMID] [PMCID]
Stefoski D, Schauf CL, McLeod BC, Davis FA. Plasmapheresis decreases neuroelectric blocking activity in multiple sclerosis. Neurology. 1982; 32(8):907. [DOI:10.1212/WNL.32.8.904]
Comabella M, Lünemann JD, Río J, Sánchez a, López C, Julià E, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009; 132(Pt 12):3353–65. [DOI:10.1093/brain/awp228] [PMID]
Rudick RA, Goelz SE. Beta-interferon for multiple sclerosis. Experimental Cell Research. 2011; 317(9):1301–11. [DOI:10.1016/j.yexcr.2011.03.002] [PMID]
Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica. 2006; 113(5):283–7. [DOI:10.1111/j.1600-0404.2006.00585.x] [PMID]
Mokhber N, Azarpazhooh A, Orouji E, Khorram B, Modares Gharavi M, Kakhi S, et al. Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry and Clinical Neurosciences. 2015; 69(10):649–57. [DOI:10.1111/pcn.12308] [PMID]
Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology. 2011; 69(1):75–82. [DOI:10.1002/ana.22316] [PMID]
Twork S, Nippert I, Scherer P, Haas J, Pöhlau D, Kugler J. Immunomodulating drugs in multiple sclerosis: Compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Current Medical Research and Opinion. 2007; 23(6):1209–15. [DOI:10.1185/030079907X188125] [PMID]
Rice CM, Cottrell D, Wilkins A, Scolding NJ. Primary progressive multiple sclerosis: progress and challenges. Journal of Neurology, Neurosurgery, and Psychiatry. 2013; 84(10):1100–6. [DOI:10.1136/jnnp-2012-304140] [PMID]
Neuhaus O, Kieseier BC, Hartung H-P. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacology & Therapeutics. 2006; 109(1-2):198–209. [DOI:10.1016/j.pharmthera.2005.07.002] [PMID]
Esposito F, Radaelli M, Martinelli V, Sormani MP, Martinelli Boneschi F, Moiola L, et al. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis Journal. 2010; 16(12):1490–9. [DOI:10.1177/1352458510379613] [PMID]
Chataway J, Miller DH. Natalizumab therapy for multiple sclerosis. Neurotherapeutics. 2013; 10(1):19–28. [DOI:10.1007/s13311-012-0171-4] [PMID] [PMCID]
Pelletier D, Hafler DA. Fingolimod for Multiple Sclerosis. The New England Journal of Medicine. 2012; 366:339–47. [DOI:10.1056/NEJMct1101691] [PMID]
Brown BA, Kantesaria PP, McDevitt LM. Fingolimod: A novel immunosuppressant for Multiple Sclerosis. Annals of Pharmacotherapy. 2007; 41(10):1660–8. [DOI:10.1345/aph.1G424] [PMID]
Morris K, Yiannikas C. Treatment update in multiple sclerosis. Current Allergy and Asthma Reports. 2012; 12(3):246–54. [DOI:10.1007/s11882-012-0256-5] [PMID]
Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine. 2012; 18(2):128–34. [DOI:10.1016/j.molmed.2011.10.004] [PMID]
Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006; 107(1):367–72. [DOI:10.1182/blood-2005-07-2657] [PMID]
Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Research & Therapy. 2011; 2(4):34–43. [DOI:10.1186/scrt75] [PMID] [PMCID]
Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell – natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs , whereas MSCs can inhibit IL-2 – induced NK-cell proliferation. Blood. 2015; 107(4):1484–91. [DOI:10.1182/blood-2005-07-2775] [PMID]
Wei X, Yang X, Han Z, Qu F, Shao L, Shi Y. Mesenchymal stem cells: A new trend for cell therapy. Acta Pharmacologica Sinica. 2013; 34(6):747–54. [DOI:10.1038/aps.2013.50] [PMID] [PMCID]
Ramasamy R, Fazekasova H, Lam EW-F, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 2007; 83(1):71–6. [DOI:10.1097/01.tp.0000244572.24780.54] [PMID]
Davila C, Dulamea A. Mesenchymal stem cells in multiple sclerosis-translation to clinical trials. Journal of Medicine and Life. 2015; 8(1):24-7. [PMID] [PMCID]
El-Jawhari JJ, El-Sherbiny YM, Jones EA, McGonagle D. Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. International Journal of Medicine. 2014; 107(7):505-14. [DOI:10.1093/qjmed/hcu033] [PMID] [PMCID]
Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: Mesenchymal stem cells and macrophages move in.Journal of Experimental Medicine. 2011; 208(3):421–8. [DOI:10.1084/jem.20110132] [PMID] [PMCID]
Isern J, García-García A, Martín AM, Arranz L, Martín-Pérez D, Torroja C, et al. The neural crest is a source of mesenchymal stem cells with specialized hematopoietic stem cell niche function. eLife. 2014; 3:e03696. [DOI:10.7554/eLife.03696] [PMID] [PMCID]
Gerdoni E, Gallo B, Casazza S, Musio S, Bonanni I, Pedemonte E, et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Annals of Neurology. 2007; 61:219–27. [DOI:10.1002/ana.21076] [PMID]
Chang JT, Palanivel VR, Kinjyo I, Schambach F, Intlekofer AM, Banerjee A, et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science. 2007; 315(5819):1687–91. [DOI:10.1126/science.1139393] [PMID]
MacQueen L, Sun Y, Simmons CA. Mesenchymal stem cell mechanobiology and emerging experimental platforms. Journal of the Royal Society Interface. 2013; 10(84):20130179. [DOI:10.1098/rsif.2013.0179] [PMID] [PMCID]
Shi Y, Hu G, Su J, Li W, Chen Q, Shou P, et al. Mesenchymal stem cells: A new strategy for immunosuppression and tissue repair. Cell Research. 2010; 20(5):510–8. [DOI:10.1038/cr.2010.44] [PMID]
Tokoyoda K, Hauser AE, Nakayama T, Radbruch A. Organization of immunological memory by bone marrow stroma. Nature Reviews Immunology. 2010; 10(3):193–200. [DOI:10.1038/nri2727] [PMID]
Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: A model for neutrophil preservation in the bone marrow niche. Stem Cells Journals. 2008; 26(1):151–62. [DOI:10.1634/stemcells.2007-0416] [PMID]
Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nature Immunology. 2014; 15(11):1009–16. [DOI:10.1038/ni.3002] [PMID]
Al Jumah M a, Abumaree MH. The Immunomodulatory and Neuroprotective Effects of Mesenchymal Stem Cells (MSCs) in Experimental Autoimmune Encephalomyelitis (EAE): A Model of Multiple Sclerosis (MS). International Journal of Molecular Sciences. 2012; 13(7):9298–331. [DOI:10.3390/ijms13079298] [PMID] [PMCID]
Ben-Ami E, Berrih-Aknin S, Miller A. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmunity Reviews. 2011; 10(7):410–5. [DOI:10.1016/j.autrev.2011.01.005]
Arsenio J, Kakaradov B, Metz PJ, Kim SH, Yeo GW, Chang JT. Early specification of CD8+ T lymphocyte fates during adaptive immunity revealed by single-cell gene-expression analyses. Nat Immunol. 2014; 15(4):365–72. [DOI:10.1038/ni.2842] [PMID] [PMCID]
Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nature Medicine. 2007; 13(2):139–45. [DOI:10.1038/nm1551]
Goto H, Matsuo H, Nakane S, Izumoto H, Fukudome T, Kambara C, et al. Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Therapeutic Apheresis and Dialysis. 2001; 5(6):494–6. [DOI:10.1046/j.1526-0968.2001.00386.x] [PMID]
Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, Sweeney EM, et al. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. European Journal of Immunology. 2011; 41(10):2840–51. [DOI:10.1002/eji.201141499] [PMID]
Favaro E, Carpanetto A, Lamorte S, Fusco A, Caorsi C, Deregibus MC, et al. Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. Diabetologia. 2014; 57(8):1664–73. [DOI:10.1007/s00125-014-3262-4] [PMID]
Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. The New England Journal of Medicine. 2009; 361(9):888–98. [DOI:10.1056/NEJMra0707449] [PMID]
Ghannam S, Pène J, Moquet-Torcy G, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. The Journal of Immunology. 2010; 185(1):302–12. [DOI:10.4049/jimmunol.0902007] [PMID]
Ghoreschi K, Laurence A, Yang X-P, Hirahara K, O’Shea JJ. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends in Immunology. 2011; 32(9):395–401. [DOI:10.1016/j.it.2011.06.007]
Chang JT, Wherry EJ, Goldrath AW. Molecular regulation of effector and memory T cell differentiation. Nature Immunology. 2014; 15(12):1104–15. [DOI:10.1038/ni.3031] [PMID] [PMCID]
Tang Q, Bluestone JA. The Foxp3+regulatory T cell: A jack of all trades, master of regulation. Nature Immunology. 2008; 9(3):239–44. [DOI:10.1038/ni1572] [PMID] [PMCID]
Zhao Z, Wu Y, Cheng M, Ji Y, Yang X, Liu P, et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis. 2011; 217(2):518–24. [DOI:10.1016/j.atherosclerosis.2011.03.043] [PMID]
Benvenuto F, Ferrari S, Gerdoni E, Gualandi F, Frassoni F, Pistoia V, et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells. 2007; 25(7):1753–60. [DOI:10.1634/stemcells.2007-0068] [PMID]
Dazzi F, Krampera M. Mesenchymal stem cells and autoimmune diseases. Best Practice & Research Clinical Haematology. 2011; 24(1):49–57. [DOI:10.1016/j.beha.2011.01.002] [PMID]
Zhou H, Gao Y, Tian HM. [Bone marrow mesenchymal stem cell therapy on diabetic nephropathy in rats (Chinese)]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009; 40(6):1024–8. [PMID]
Dazzi F, Horwood NJ. Potential of mesenchymal stem cell therapy. Current Opinion in Oncology. 2007; 19(6):650–5. [DOI:10.1097/CCO.0b013e3282f0e116] [PMID]
Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. The Journal of Immunology. 2010; 185(1):302–12. [DOI:10.4049/jimmunol.0902007] [PMID]
Lanz TV, Opitz CA, Ho PP, Agrawal A, Lutz C, Weller M, et al. Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells and Development. 2010; 19(5):657–68. [DOI:10.1089/scd.2009.0385] [PMID] [PMCID]
Abumaree M, Al Jumah M, Pace RA, Kalionis B. Immunosuppressive Properties of Mesenchymal Stem Cells. Stem Cell Reviews and Reports. 2011; 8(2):375–92. [DOI:10.1007/s12015-011-9312-0]
Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. The Journal of Immunology. 2009; 182(21):5994–6002. [DOI:10.4049/jimmunol.0803962] [PMID]
Rafei M, Birman E, Forner K, Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Molecular Therapy. 2009; 17(10):1799–803. [DOI:10.1038/mt.2009.157] [PMID] [PMCID]
Fisher-Shoval Y, Barhum Y, Sadan O, Yust-Katz S, Ben-Zur T, Lev N, et al. Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS. Journal of Molecular Neuroscience. 2012; 48(1):176–84. [DOI:10.1007/s12031-012-9805-6] [PMID]
Yang SH, Park MJ, Yoon IH, Kim SY, Hong SH, Shin JY, et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Experimental & Molecular Medicine. 2009; 41(5):315–24. [DOI:10.3858/emm.2009.41.5.035] [PMID] [PMCID]
Yu J, Zheng C, Ren X, Li J, Liu M, Zhang L, et al. Intravenous administration of bone marrow mesenchymal stem cells benefits experimental autoimmune myasthenia gravis mice through an immunomodulatory action. Scandinavian Journal of Immunology. 2010; 72(3):242–9. [DOI:10.1111/j.1365-3083.2010.02445.x] [PMID]
Sui W, Hou X, Che W, Chen J, Ou M, Xue W, et al. Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. Clinical Immunology. 2013; 148(2):186–97. [DOI:10.1016/j.clim.2013.05.014] [PMID]
Domínguez-Bendala J, Lanzoni G, Inverardi L, Ricordi C. Concise review: mesenchymal stem cells for diabetes. Stem Cells Translational Medicine. 2012; 1(1):59–63. [DOI:10.5966/sctm.2011-0017] [PMID] [PMCID]
Flores AI, Gómez-Gómez GJ, Masedo-González Á, Martínez-Montiel MP. Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy? World Journal of Stem Cells. 2015; 7(2):343–51. [DOI:10.4252/wjsc.v7.i2.343] [PMID] [PMCID]
Wang X, Kimbrel EA, Ijichi K, Paul D, Lazorchak AS, Chu J, et al. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Reports. 2014; 3(1):115–30. [DOI:10.1016/j.stemcr.2014.04.020] [PMID] [PMCID]
Meamar R, Nematollahi S, Dehghani L, Mirmosayyeb O, Shayegannejad V, Basiri K, et al. The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies. 2016; 5:46. [DOI:10.4103/2277-9175.178791] [PMID] [PMCID]
Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007; 25(11):2739–49. [DOI:10.1634/stemcells.2007-0197] [PMID]
Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of Multiple Sclerosis. Journal of the Neurological Sciences. 2012; 313(1-2):167–77. [DOI:10.1016/j.jns.2011.08.036] [PMID]
Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S, et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. JAMA Neurology. 2008; 65(6):753–61. [DOI:10.1001/archneur.65.6.753] [PMID]
Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells. 2009; 27(10):2624–35. [DOI:10.1002/stem.194] [PMID]
Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009; 57(11):1192–203. [DOI:10.1002/glia.20841] [PMID] [PMCID]
Zhang J, Li Y, Chen J, Cui Y, Lu M, Elias SB, et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Experimental Neurology. 2005; 195(1):16–26. [DOI:10.1016/j.expneurol.2005.03.018] [PMID]
Lanza C, Morando S, Voci A, Canesi L, Principato MC, Serpero LD, et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. Journal of Neurochemistry. 2009; 110:1674–84. [DOI:10.1111/j.1471-4159.2009.06268.x] [PMID]
Gordon D, Pavlovska G, Glover CP, Uney JB, Wraith D, Scolding NJ. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neuroscience Letters. 2008; 448(1):71–3. [DOI:10.1016/j.neulet.2008.10.040] [PMID] [PMCID]
Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T cell anergy. Blood. 2005; 106(5):1755–61. [DOI:10.1182/blood-2005-04-1496] [PMID]
Zhang J, Li Y, Lu M, Cui Y, Chen J, Noffsinger L, et al. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. Journal of Neuroscience Research. 2006; 84(3):587–95. [DOI:10.1002/jnr.20962] [PMID]
Payne NL, Dantanarayana A, Sun G, Moussa L, Caine S, McDonald C, et al. Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination. Cell Adhesion & Migration. 2012; 6(3):179–89. [DOI:10.4161/cam.20341] [PMID] [PMCID]
Ryu CH, Park KY, Hou Y, Jeong CH, Kim SM, Jeun SS. Gene therapy of Multiple Sclerosis using interferonβ-secreting human bone marrow mesenchymal stem cells. BioMed Research International. 2013; 2013:1–9. [DOI:10.1155/2013/696738]
Payne NL, Sun G, McDonald C, Moussa L, Emerson-Webber A, Loisel-Meyer S, et al. Human adipose-derived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity. Brain, Behavior, and Immunity. 2013; 30:103–14. [DOI:10.1016/j.bbi.2013.01.079]
Yousefi F, Ebtekar M, Soudi S, Soleimani M, Hashemi SM. In vivo immunomodulatory effects of adipose-derived mesenchymal stem cells conditioned medium in experimental autoimmune encephalomyelitis. Immunology Letters. 2016; 172:94-105. [DOI:10.1016/j.imlet.2016.02.016]
Yousefi F, Ebtekar M, Soleimani M, Soudi S, Hashemi SM. Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in Experimental Autoimmune Encephalomyelitis (EAE). International Immunopharmacology. 2013; 17(3):608–16. [DOI:10.1016/j.intimp.2013.07.016] [PMID]
Mohammadzadeh A, Pourfathollah AA, Shahrokhi S, Fallah A, Tahoori MT, Amari A, et al. Evaluation of AD-MSC (Adipose derived -Mesenchymal stem cells) as a vehicle for IFN-β delivery in Experimental Autoimmune Encephalomyelitis. Clinical Immunology. 2016; 169:98–106. [DOI:10.1016/j.clim.2016.06.015]
Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, Hooshmand F, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iranian Journal of Immunology. 2007; 4(1):50-7. [DOI:IJIv4i1A7] [PMID]
Gharibi T, Ahmadi M, Seyfizadeh N, Jadidi-Niaragh F, Yousefi M. Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of Multiple Sclerosis. Cellular Immunology. 2015; 293(2):113–21. [DOI:10.1016/j.cellimm.2015.01.002]
Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. Journal of Neuroimmunology. 2010; 227(1-2):185–9. [DOI:10.1016/j.jneuroim.2010.07.013] [PMID]
Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. JAMA Neurology. 2010; 67(10):1187–94. [DOI:10.1001/archneurol.2010.248] [PMID] [PMCID]
Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. The Lancet Neurology. 2012; 11(2):150–6. [DOI:10.1016/S1474-4422(11)70305-2]
Hammadi AMA, Marino A, Farhan S. Clinical outcome of 50 progressive multiple sclerosis patients treated with cellular therapy in Iraq. International Journal of Stem Cells. 2011; 4(2):113–5. [PMCID] [PMID]
Odinak MM, Bisaga GN, Novitskiĭ A V, Tyrenko V V, Fominykh MS, Bilibina AA, et al. [Transplantation of mesenchymal stem cells in multiple sclerosis (Russian])]. Zh Nevrol Psikhiatr Im S S Korsakova. 2011; 111(2 Pt 2):72–6. [PMID]
Mohyeddin Bonab M, Ali Sahraian M, Aghsaie A, Ahmadi Karvigh S, Massoud Hosseinian S, Nikbin B, et al. Autologous mesenchymal stem cell therapy in progressive Multiple Sclerosis: An open label study. Current Stem Cell Research & Therapy. 2012; 7(6):407–14. [DOI:10.2174/157488812804484648]
Mohajeri M, Farazmand A, Mohyeddin Bonab M, Nikbin B, Minagar A. FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy. Iranian Journal of Allergy, Asthma and Immunology. 2011; 10(3):155–61. [DOI:010.03/ijaai.155161] [PMID]
Mohyeddin Bonab M, Mohajeri M, Sahraian MA, Yazdanifar M, Aghsaie A, Farazmand A, et al. Evaluation of cytokines in multiple sclerosis patients treated with mesenchymal stem cells. Archives of Medical Research. 2013; 44(4):266–72. [DOI:10.1016/j.arcmed.2013.03.007]
Hou ZL, Liu Y, Mao XH, Wei CY, Meng MY, Liu YH, et al. Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis. Cell Adhesion & Migration. 2013; 7(5):404-7. [DOI:10.4161/cam.26941] [PMID] [PMCID]